To take competition out from Omontys. Hope they don't get caught like
FDA halts pediatric study of Amgen's Sensipar after death
Sensipar is a drug that got special price protections in fiscal cliff legislation
February 27, 2013 | By Eric Palmer
The FDA has halted a study in children of the Amgen ($AMGN) drug Sensipar after a 14-year-old died during the trial. While the FDA says it does not know yet if the drug was the cause of the death, it halted the trial as a precaution. Sensipar stirred up ire last month when it was learned that the drug received special price protections in the fiscal cliff bill.
"Posting this information does not mean that FDA has concluded whether or not Sensipar had a role in the patient's death," the FDA said in a statement. "This communication is intended to inform health care professionals that we are evaluating the information and will communicate our final conclusions and recommendations when our review is complete."
Amgen said it is "working as rapidly as possible to understand the circumstances of what happened," CBS News reported.